isabelobrien, Author at European Medical Journal - Page 29 of 66

ABPI calls for MHRA reform to drive UK life sciences growth

As the MHRA begins a new chapter, the ABPI has published a report outlining the importance of regulatory excellence in the UK.

Season 8 highlights: GOLD Medal Moments

Season 8 is almost over, but before we release our finale episode, why not take a listen to some of our favourite moments from the series just gone?

cancer illustration

Novocure’s Phase III trial shows promise for pancreatic cancer

The Phase 3 PANOVA-3 trial has shown that adding Tumor Treating Fields therapy to standard chemotherapy improved survival in patients.

Orange lungs on yellow background

AstraZeneca supports first asthma and COPD breakthrough in 50 years

Research supported by AstraZeneca has demonstrated that a single dose of benralizumab significantly reduces treatment failure rates – by four times compared to traditional steroid tablets.

Donald Trump picks last role in health leadership team

President-elect Donald Trump has picked the final post in his health team, selecting Dr Jay Bhattacharya to be Director of the US National Institutes of Health.

Fostering trust between pharma and HCPs

This infographic explores the state of trust between the healthcare and pharmaceutical industries, assessing where they stand in the rankings, how valuable pharma-HCP interactions can be and more.

Europe's biopharma SMEs need urgent support, warns EFPIA

Europe must act urgently to back small and medium-sized enterprises (SMEs) in the biopharmaceutical sector, says the EFPIA.

Elias Revonta, Orcason Medical

World AMR Awareness Week with Orcason Medical’s Elias Revonta

Elias Revonta, Founder & CEO, Orcason Medical, joins the podcast to discuss why the fight against AMR needs to extend beyond awareness weeks.

First anti-TFPI for haemophilia approved in EU

Pfizer’s anti-tissue factor pathway inhibitor has been approved for the treatment of haemophilia A & B by the European Commission.

Handshake on blue background

FDA greenlights UCB’s IL-17 inhibitor for HS

The novel IL-17A and IL-17F inhibitor has been approved the treatment of moderate to severe hidradenitis suppurativa, a chronic and painful skin disease.